LONDON - A breakthrough cancer treatment plan could be a "cure" for a death sentence form of the disease. An experimental new treatment being pioneered by Dr Paul Mulholland, a brain cancer specialist at University College London, has proved remarkably successful for some patients - and experts say it could be available within five years. Brain
ANN ARBOR - Don't miss the 2024 Michigan Medical Device Summit happening in Ann Arbor on September 23rd. With less than two weeks to go, now is the time to secure your spot at this pivotal event for medtech professionals. Join us for an exclusive FDA Town Hall where you'll gain firsthand insights from FDA
NEW YORK - That if our lifespan could be extended beyond its natural limits? Recently, scientists have made a significant leap towards this very real possibility with the discovery and study of an important longevity gene. This gene has shown promise in promoting cellular repair and reducing the effects of aging, generating excitement in the
NEW YORK - A drug commonly used to induce labor could offer new hope in the fight against Alzheimer's disease, according to recent research. Scientists have discovered that this medication, which has been used for decades to help pregnant women, may also revitalize the brain's waste removal system - a system that often becomes impaired in Alzheimer's patients. Alzheimer's and other dementias
NEW YORK – DDL-920 Reversing the Symptoms of Alzheimer's Disease could mark a significant breakthrough in the treatment of this debilitating condition. While current therapies primarily focus on targeting the physical manifestations of Alzheimer's, such as amyloid plaques, a new approach is emerging. Rather than concentrating on combating the plaques associated with Alzheimer's disease, researchers
SWEDEN - Can a blood test based on the ratio of plasma phosphorylated tau 217 (p-tau217) relative to non–p-tau217 (expressed as percentage of p-tau217) combined with the amyloid-β 42 and amyloid-β 40 plasma ratio (the amyloid probability score 2 [APS2]) accurately identify Alzheimer disease in primary care and secondary care when prospectively applying predefined biomarker
NEW YORK - The scientific community has long been interested in understanding and extending human life. In a new piece of research, published in Nature,Trusted Source researchers at the Medical Research Council Laboratory of Medical Science and Imperial College London, in collaboration with Duke-NUS Medical School, administered an anti-IL-11 antibody — a drug that inhibits IL-11’s effects
Have you ever wished you could slow down the ticking clock of aging? Science might have come a smidgen closer to granting your wish. Researchers have developed a new anti-aging drug that claims to significantly increase lifespan, adding up to 25% more healthy, vibrant years. The brain behind this exciting development is none other than
WASHINGTON DC - The Food and Drug Administration approved a new Alzheimer's treatment called donanemab on Tuesday, clearing the way for the third addition to a new class of drugs aimed at slowing the brain's decline in patients facing the early stages of the disease. Branded as Kisunla by drugmaker Eli Lilly, donanemab's approval follows
KALAMAZOO–Stryker Corp. announced an agreement to acquire all of the shares of Artelon Inc., a Marietta, Ga.-based privately held maker of soft tissue fixation products for foot and ankle and sports medicine procedures. Stryker officials said the company will strengthen its offerings in the soft tissue fixation segment and highlights Stryker’s commitment to providing differentiated
Notifications
